CEO Susan Cantrell previews AMCP Nexus 2026, discussing AI, drug pricing, emerging therapies, and a decade of change in managed care pharmacy.
|Webinars|August 24, 2020
Changing Patterns of Care in Multiple Myeloma
Current therapeutic options for multiple myeloma and best practices in dispensing medications throughout the COVID-19 pandemic.
Advertisement
Advertisement
Related to this article
At ASN Kidney Week 2026, nephrologists said value-based kidney models improved dialysis starts, but payment cuts and MA growth are pushing practices out.
At IDWeek 2026, IDSA and HIVMA leaders and clinician advocates outline how stories, relationships, and bipartisan outreach shape ID and HIV policy.
Jennifer Flythe, MD, MPH, discusses individualizing dialysis volume management and why guideline-directed therapy use lags in advanced CKD.
Povetacicept reduced proteinuria by 52% vs 4.3% with placebo at week 36 in adults with IgA nephropathy in the phase 3 RAINIER trial’s interim analysis.
At IDWeek 2026, Atul Gawande, MD, MPH, said USAID cuts are costing lives but that the field is "not back at square one."
Oncologists weighted how to choose, manage, and deliver new therapeutics beyond major academic centers.
As CKCC nears its sunset, kidney care leaders urge CMS to preserve a dedicated, nephrologist-led accountable care model for advanced kidney disease.
Advertisement
Advertisement
Trending on AJMC
1
Merck, Moderna Cancer Vaccine Cuts Melanoma Recurrence Risk by 42%
2
Nephrologists Weigh Wins, Losses From 5 Years of Value-Based Kidney Care
3
Povetacicept Cuts Proteinuria by 52% in IgA Nephropathy at Week 36
4
Dialysis Access, Church CKD Screening Address Kidney Care Inequities
5